SSTR1
Somatostatin receptor type 1
As of the edition of 20 October 2026, SSTR1 (somatostatin receptor type 1, UniProt P30872) has 6 drugs tested at it and 13 companies on the list, 1 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P30872
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Cancer; Hormones; Digestive system; Nervous system; Bones, joints and muscles; Nutrition and metabolism; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 260
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Octreotide | Marketed | Phase 4 | none listed |
| Lutetium oxodotreotide | Marketed | Phase 4 | Ends 2031 |
| Somatostatin | Marketed | Phase 4 | none listed |
| Indium pentetreotide | Marketed | Phase 4 | none listed |
| Lutetium-177 | Status not established | No phase stated | none listed |
| Lutetium chloride | Withdrawn from market | No phase stated | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 4 |
| Engaged | 3 |
| Undetermined | 5 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Curium | Route B |
| Camurus | Route B |
| ITM Medical Isotopes | Route A |
The other 10 companies at SSTR1
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at SSTR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.